79P - Molecular targeted therapy for Her2 positive breast cancer in private sector: Yangon experience

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Breast Cancer, Early Stage
Biomarkers
Presenter Myo Khine
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors M. Khine1, S. Mon2, N. Sein1, T.T. Aye3, S.S. Htay2, N.H. Kyaw1, E.P.P. Aung1, P.T. Hnin1
  • 1Oncology, Thurein Oncology Clinic, 11131 - Yangon/MM
  • 2Medical Oncology, Bahosi Medical Centre Bahosi Housing Complex, 11131 - Yangon/MM
  • 3Medical Oncology, Bahosi Medical Centre Bahosi Housing Complex, 1221 - Yangon/MM

Abstract

Background

Trastuzumab in combination with chemotherapy is approved for treatment of early and metastatic Her2 over expressing breast cancer and shown to increase survival. But cost of trastuzumab makes the patients hurdle to get access the standard treatment in low income countries.

Methods

Clinical data of patients with breast cancer at 3 private clinics in Yangon, Myanmar from July 2014 to June 2016 were studied and analyzed for molecular subtype distribution and access to Her2 targeted therapy in Her2 positive breast cancer patients.

Results

Including 2 male breast cancer patients, a total of 488 breast cancer patients were registered. Mean age is 52.73 yrs (range 22yrs - 87yrs). Invasive duct carcinoma were 92% (n = 449). Biological markers ER, PR, Her2 status were done with Immunohistochemistry method in 82.5% (n = 407) whereas 8.23% were not done the test due to financial limitations. Molecular subtypes were 39.8% (n = 162) with ER positive Her2 negative and 17.93% (n = 73) with Triple Negative Breast cancer. Total Her2 positive patients were 37.83% (n = 154) which was relatively high number and all were female. 4.5% of Her2 positive patients were Stage I, 70.12% were Stage II and 18.18% and 7.14% were Stage III and IV. 42 patients (27.27%) received Trastuzumab therapy either intravenous or subcutaneous injection forms. 3 patients with advanced cancer also received combination with Pertuzumab. Among 42 patients, 3 patients stopped trastuzumab treatment after 8th and 9th cycle due to financial catastrophe during therapy.

Conclusions

Although there is patient assistance program to get access for Trastuzumab for Her2 positive breast cancer in Myanmar, still limited number of patients can afford for the treatment in private sector cancer care. Access to treatment and cost of therapy are barriers for Her2 targeted therapy in developing countries like Myanmar where the health care expenditure is totally out of pocket for cancer patients.

Clinical trial indentification

Legal entity responsible for the study

Thurein Oncology Clinic

Funding

Thurein Oncology Clinic

Disclosure

All authors have declared no conflicts of interest.